Sanaria recognized as a NIH SBIR/STTR Notable Success

“NIH SBIR funding provided Sanaria with critical early-stage dollars to get our lead vaccine off the ground. Without this funding, Sanaria would have never gotten started and our malaria vaccine would not exist. No other investor would have provided money for this type of high-risk research.”

– Dr. Steve Hoffman, CEO of Sanaria

Read the full NIH SBIR story!